Fig. 6
From: Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice
Immunoglobulin-bound Aβ detected in oligomers, protofibrils and fibrils in APP23 mice: Effects of β1 antibody treatment. Semiquantitative analysis of western blots after immunoprecipitation of immunoglobulin (antibody)-bound Aβ by precipitation of antibodies with protein G-coated magnetic beads. Subsequent western blot analysis with anti-Aβ1–17 revealed antibody-bound Aβ in the dispersible fraction of both β1- and PBS-treated mice at both ages. In 5-month-old β1-treated APP23 mice antibody-bound Aβ was found in the soluble fraction whereas no antibody-bound Aβ was precipitated in PBS-treated animals (* p < 0.05). At 11-months of age both, β1 and PBS-treated animals exhibited antibody bound soluble Aβ in similar amounts. Antibody-bound AβN3pE was not observed whereas 11-month-old (but not 5-month-old) APP23 mice showed similar amounts of dispersible antibody-bound pAβ. No soluble antibody-bound pAβ was seen. Graphs represent mean values (white symbols 5-month-old mice; black symbols 11-month-old mice) and standard errors (whiskers). (Full blots Additional file 10: Figure S7; Statistical analysis in Additional file 3: Table S3)